Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Adv Drug Deliv Rev. 2013 Mar;65(3):342-7. doi: 10.1016/j.addr.2012.07.002. Epub 2012 Jul 6.
Exosomal particular size of 30-100 nm matches the size criterion for nanoparticles, and opens up the possibility of using exosomes as a nanoparticle drug carrier. More importantly, exosomes released from different types of host cells have different biological effects and targeting specificities. Therefore, depending on the therapeutic goal, different types of exosomes can be combined with specific drugs and serve as carriers so that personalized medicine needs are met. In addition, exosomes do not appear to have cytotoxicity. Based on the perceived advantages of exosomes, they may well serve as a next generation drug delivery mechanism that combines nanoparticle size with a non-cytotoxic effect, target specificity, and a high drug carrying capacity, to make them useful in the treatment of a variety of diseases. This review will focus on exosomes as a biological nanoparticle drug carrier with emphasis on their immune-regulatory activities.
外泌体的特殊大小为 30-100nm,符合纳米颗粒的尺寸标准,为外泌体作为纳米颗粒药物载体开辟了可能性。更重要的是,不同类型的宿主细胞释放的外泌体具有不同的生物学效应和靶向特异性。因此,根据治疗目标,可以将不同类型的外泌体与特定药物结合并用作载体,从而满足个性化医疗的需求。此外,外泌体似乎没有细胞毒性。基于对外泌体的优势的认识,它们很可能成为下一代药物输送机制,将纳米颗粒的大小与非细胞毒性、靶向特异性和高载药能力结合起来,使其在治疗多种疾病方面发挥作用。这篇综述将重点介绍外泌体作为一种生物纳米颗粒药物载体,重点介绍其免疫调节活性。